NEW YORK – Bio-Rad Laboratories and Stilla Technologies have settled a patent infringement lawsuit in the US District Court District of Massachusetts.
Terms of the settlement were not immediately available.
The suit was originally brought in 2019 by Bio-Rad together with plaintiffs The University of Chicago, Lawrence Livermore National Security, and Harvard University.
It alleged that Stilla's Naica digital PCR system infringed on four patents held or licensed by Bio-Rad, namely US patent numbers 9,968,933; RE41,780; 8,871,444; and 9,127,310.
The suit was officially settled and dismissed on July 3, 2021.
The '310 patent is also a subject of an infringement lawsuit Bio-Rad filed last year against Dropworks, while the '444 patent has been one of the subjects of IP litigation the firm filed against 10x Genomics.
Simon May, Bio-Rad's senior VP of the digital biology group, commented that the firm is pleased to have reached a settlement with Stilla Technologies related to the use of droplets for digital PCR.
“We believe this resolution validates the broadening value of Bio-Rad's IP portfolio of products and applications that accelerate scientific discovery and improve healthcare,” May said.
Philippe Mourere, Stilla Technologies' president and CEO, said the firm is also pleased to have settled its dispute with Bio-Rad, and that it "will continue to scale up operations" in support of a "rapidly growing customer base and strong demand" for its next-generation digital PCR systems.
"Digital PCR has come of age and is accelerating breakthroughs across the research and diagnostics spectrum in oncology, infectious diseases, gene therapy, disease monitoring, and food testing," Mourere said.